Cargando…

Genome-wide prioritization reveals novel gene signatures associated with cardiotoxic effects of tyrosine kinase inhibitors

Tyrosine kinase inhibitors (TKIs) are characterized as multi-targeted anticancer agents that lack specificity, leading to cardiovascular adverse effects. To date, there are no reliable means to predict the cardiotoxicity of TKIs under development. The present study assessed the usual variants of gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yilan, Wang, Weijie, Gao, Rong, Xu, Xueming, Zhang, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751338/ https://www.ncbi.nlm.nih.gov/pubmed/33376527 http://dx.doi.org/10.3892/ol.2020.12355

Ejemplares similares

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity
por: Xiong, Yuguang, et al.
Publicado: (2022)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
por: Sestier, Maude, et al.
Publicado: (2021)

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
por: Kim, Lisa, et al.
Publicado: (2021)

Mechanisms of Cardiotoxicity Associated with Tyrosine Kinase Inhibitors in H9c2 Cells and Mice
por: Bouitbir, J, et al.
Publicado: (2020)

Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes
por: Wang, Huan, et al.
Publicado: (2023)

Deconvoluting Kinase Inhibitor Induced Cardiotoxicity
por: Lamore, Sarah D., et al.
Publicado: (2017)

Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
por: Franczyk, Beata, et al.
Publicado: (2023)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022)

Analysis and Validation of Differentially Expressed Ferroptosis-Related Genes in Regorafenib-Induced Cardiotoxicity
por: Zhang, Siyuan, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
por: Bauer, Michael A., et al.
Publicado: (2021)

Genome-Wide Identification and Characterization of Tyrosine Kinases in the Silkworm, Bombyx mori
por: He, Songzhen, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
por: Ashby, Michael, et al.
Publicado: (2020)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
por: Cha, Kihoon, et al.
Publicado: (2016)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Alteration of N(6)-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity
por: Ma, Yan, et al.
Publicado: (2022)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Genome-wide screen of gamma-secretase–mediated intramembrane cleavage of receptor tyrosine kinases
por: Merilahti, Johannes A. M., et al.
Publicado: (2017)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Genomic signatures reveal selection in Lingxian white goose
por: Zheng, Sumei, et al.
Publicado: (2022)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase
por: Kimani, Stanley G., et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hk4g1gklv91uq43fu1jhui5ph6